AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News

$4.31
-0.12 (-2.71 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.29
Now: $4.31
$4.45
50-Day Range
$3.72
MA: $4.58
$5.05
52-Week Range
$2.55
Now: $4.31
$7.67
Volume1.75 million shs
Average Volume2.05 million shs
Market Capitalization$445.72 million
P/E Ratio10.78
Dividend YieldN/A
Beta2.01
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More
Catalyst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.31 million
Cash Flow$0.31 per share
Book Value$0.96 per share

Profitability

Net Income$31.88 million

Miscellaneous

Employees51
Market Cap$445.72 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

How has Catalyst Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPRX stock has increased by 22.4% and is now trading at $4.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catalyst Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Pharmaceuticals.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Catalyst Pharmaceuticals.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.09 by $0.01. The biopharmaceutical company had revenue of $29.14 million for the quarter, compared to the consensus estimate of $31.68 million. Catalyst Pharmaceuticals had a return on equity of 52.28% and a net margin of 36.09%. View Catalyst Pharmaceuticals' earnings history.

What price target have analysts set for CPRX?

4 analysts have issued 1-year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 120.4% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals.

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

News stories about CPRX stock have trended extremely positive recently, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 4.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View the latest news aboutCatalyst Pharmaceuticals.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 12,210,000 shares, a drop of 12.8% from the April 30th total of 14,010,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is currently 5.8 days. Approximately 12.7% of the shares of the stock are sold short. View Catalyst Pharmaceuticals' Current Options Chain.

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX) and Micron Technology (MU).

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
  • Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
  • Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.19%), State Street Corp (7.20%), Morgan Stanley (2.62%), Morgan Stanley (2.62%), Geode Capital Management LLC (1.49%) and Schroder Investment Management Group (1.28%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View institutional ownership trends for Catalyst Pharmaceuticals.

Which institutional investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, Two Sigma Investments LP, Rafferty Asset Management LLC, Wells Fargo & Company MN, Voloridge Investment Management LLC, Morgan Stanley, and Morgan Stanley. View insider buying and selling activity for Catalyst Pharmaceuticals.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was purchased by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Sontag Advisory LLC, Federated Hermes Inc., Acadian Asset Management LLC, Los Angeles Capital Management & Equity Research Inc., Russell Investments Group Ltd., AQR Capital Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, and Patrick J Mcenany. View insider buying and selling activity for Catalyst Pharmaceuticals.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $4.31.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $445.72 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.